Bildschirmfoto 2018-11-06 um 13.27.45.png

October 31, 2018
Meet us @ Bio Europe 2018 in Copenhagen
The 24th Annual International Partnering Conference takes place from November 5th to 7th in beautiful Copenhagen. TOLREMO therapeutics will be present to meet with industry partners, expand business contacts and to gain insight into latest industry trends – feel free to get in touch (info@tolremo.com). See you soon at the Bella Center in Copenhagen!


TOP5Biotech_LinkedIn.png

September 5, 2018
TOLREMO is one of the TOP 5 most promising Swiss Biotech Startups in 2018

TOLREMO therapeutics has made it directly into this year’s Top 5 Biotech Startups in Switzerland! Ranked 31st in the nation-wide rating, TOLREMO proudly takes its place as of the best 100 Swiss start-ups in the prosperous Swiss Startup ecosystem. Many thanks to all investors and experts who believe in our potential and made this outstanding achievement possible! To the article


Bildschirmfoto 2018-11-06 um 13.39.46.png

August 30, 2018
Female Founders – Von der Idee zum Erfolg

Dr. Stefanie Flückiger-Mangual, CEO & Co-founder of TOLREMO therapeutics, was invited to share her industry insights and experiences as female founder of a rapidly growing biotechnology company. Together with other entrepreneurs, the panel discussed the growing role of women in a predominantly men-dominated business and investor environment. The event was covered by the Swiss Startup News channel startupticker.ch.
-> To the startupticker.ch article
-> Download review pdf


BioCentury_Innovations_EuropesPieceofthePie_Tolremo_May_2018.png

May 17, 2018
BioCentury – TOLREMO one of Europe’s top academic spinouts

By Lauren Martz
TOLREMO therapeutics was covered by BioCentury Innovations. In ‘Europe’s Piece of the Pie’ TOLREMO was named one of Europe’s top academic spinouts with disclosed financing.
-> Read the full article here (pdf)


September 28, 2017
BioWorld – TOLREMO aims to choke cancer drug resistance at birth

By Cormac Sheridan
DUBLIN – For too many cancer patients, therapy still means no more than prolonging the inevitable. Cancer drug developers are proud to trot out numbers detailing objective response rates to novel drug candidates, along with progression-free survival and overall survival data. They're not shy about charging high prices for their product offerings either. But the grim reality is that five-year survival rates for many cancers – including lung, liver and esophageal – are still well below 50 percent, even if cancer death rates continue to decline in the U.S. and other high-income countries.
-> Buy reprint here